BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19785605)

  • 1. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
    Hartmann K; Siebenhaar F; Belloni B; Brockow K; Eben R; Hartmann B; Ruëff F; Schoepke N; Staubach P; Weber A; Maurer M
    Br J Dermatol; 2010 Jan; 162(1):185-90. PubMed ID: 19785605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
    Vena GA; Cassano N; D'Argento V; Milani M
    Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial.
    Hull C; McKeough M; Sebastian K; Kriesel J; Spruance S
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):263-7. PubMed ID: 19143902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
    Bäumer W; Wlaź P; Jennings G; Rundfeldt C
    Eur J Pharmacol; 2010 Feb; 628(1-3):226-32. PubMed ID: 19917276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
    Tosti A; Iorizzo M; Botta GL; Milani M
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miltefosine: a novel treatment option for mast cell-mediated diseases.
    Maurer M; Magerl M; Metz M; Weller K; Siebenhaar F
    J Dermatolog Treat; 2013 Aug; 24(4):244-9. PubMed ID: 22385017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
    Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
    Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
    Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of '0.05% Clobetasol + 2.5% zinc sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema: a double-blind study.
    Faghihi G; Iraji F; Shahingohar A; Saidat A
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):531-6. PubMed ID: 18284511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial.
    Campisi G; Giandalia G; De Caro V; Di Liberto C; Aricò P; Giannola LI
    Br J Dermatol; 2004 May; 150(5):984-90. PubMed ID: 15149513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial.
    Conrotto D; Carbone M; Carrozzo M; Arduino P; Broccoletti R; Pentenero M; Gandolfo S
    Br J Dermatol; 2006 Jan; 154(1):139-45. PubMed ID: 16403107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
    Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
    Beutner K; Chakrabarty A; Lemke S; Yu K
    J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
    Gong JQ; Lin L; Lin T; Hao F; Zeng FQ; Bi ZG; Yi D; Zhao B
    Br J Dermatol; 2006 Oct; 155(4):680-7. PubMed ID: 16965415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
    Jarratt M; Breneman D; Gottlieb AB; Poulin Y; Liu Y; Foley V
    J Drugs Dermatol; 2004; 3(4):367-73. PubMed ID: 15303780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
    Magerl M; Rother M; Bieber T; Biedermann T; Brasch J; Dominicus R; Hunzelmann N; Jakob T; Mahler V; Popp G; Schäkel K; Schlingensiepen R; Schmitt J; Siebenhaar F; Simon JC; Staubach P; Wedi B; Weidner C; Maurer M
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e363-9. PubMed ID: 22928719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
    Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
    Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
    Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
    Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations.
    Carbone M; Arduino PG; Carrozzo M; Caiazzo G; Broccoletti R; Conrotto D; Bezzo C; Gandolfo S
    J Oral Pathol Med; 2009 Feb; 38(2):227-33. PubMed ID: 19141065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.